Clinical Trials Logo

SAPHO Syndrome clinical trials

View clinical trials related to SAPHO Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06011889 Recruiting - SAPHO Syndrome Clinical Trials

Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

SAPHO
Start date: December 13, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified classification criteria according to Kahn (2003), with the ineffectiveness of standard treatment (patient's global assessment of the disease on the VAS scale greater than or equal to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.

NCT ID: NCT04596462 Recruiting - SAPHO Syndrome Clinical Trials

Characterizing SAPHO With 68Ga-FAPI PET/CT

Start date: June 8, 2020
Phase: Early Phase 1
Study type: Interventional

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of SAPHO than 18F-FDG PET/CT.